Skip to main content

Advertisement

Table 1 Characteristics of patients with or without surgical axillary staging

From: Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?

Characteristic Whole cohort [cases (%)] Matched cohort [cases (%)]
Non-staging group Staging group P Non-staging group Staging group P
Total 6474 160,141   5561 5561  
Diagnosis year    < 0.001    0.871
 2000–2003 2779 (42.9) 47,508 (29.7)   2362 (42.5) 2364 (42.5)  
 2004–2008 2054 (31.7) 61,515 (38.4) 1759 (31.6) 1737 (31.2)
 2009–2012 1641 (25.3) 51,118 (31.9) 1440 (25.9) 1460 (26.3)
Race    < 0.001    0.423
 NHW 5130 (79.2) 124,187 (77.5)   4669 (84.0) 4601 (82.7)  
 NHB 528 (8.2) 11,880 (7.4) 353 (6.3) 353 (6.3)
 NHAIAN 22 (0.3) 681 (0.4) 7 (0.1) 9 (0.2)
 NHAPI 342 (5.3) 10,660 (6.7) 227 (4.1) 260 (4.7)
 Hispanic 430 (6.6) 12,286 (7.7) 301 (5.4) 335 (6.0)
 Unknown 22 (0.3) 447 (0.3) 4 (0.1) 3 (0.1)
Marital status    < 0.001    0.236
 Married 3089 (47.7) 99,060 (61.9)   2823 (50.8) 2738 (49.2)  
 Never married 639 (9.9) 17,685 (11.0) 474 (8.5) 491 (8.8)
 Widowed 1856 (28.7) 19,817 (12.4) 1617 (29.1) 1612 (29.0)
 Divorced 630 (9.7) 18,539 (11.6) 480 (8.6) 531 (9.5)
 Unknown 260 (4.0) 5040 (3.1) 167 (3.0) 189 (3.4)
Age (years)    < 0.001    0.525
 18–49 530 (8.2) 31,434 (19.6)   435 (7.8) 478 (8.6)  
 50–64 1623 (25.1) 69,378 (43.3) 1432 (25.8) 1394 (25.1)
 65–79 2596 (40.1) 51,559 (32.2) 2299 (41.3) 2285 (41.1)
 80– 1725 (26.6) 7770 (4.9) 1395 (25.1) 1404 (25.2)
T stage    <0.001    0.905
 T1mic 667 (10.3) 3778 (2.4)   423 (7.6) 420 (7.6)  
 T1a 1328 (20.5) 16,354 (10.2) 1105 (19.9) 1121 (20.2)
 T1b 2020 (31.2) 50,343 (31.4) 1804 (32.4) 1827 (32.9)
 T1c 2459 (38.0) 89,666 (56.0) 2229 (40.1) 2193 (39.4)
N stage    NA    NA
 N0 NA 134,137 (83.8)   NA 4977 (89.5)  
 N1 NA 22,617 (14.1) NA 527 (9.5)
 N2 NA 2552 (1.6) NA 44 (0.8)
 N3 NA 835 (0.5) NA 13 (0.2)
Histological type    <0.001    0.330
 Ductal 4616 (71.3) 122,938 (76.8)   4149 (74.6) 4079 (73.4)  
 Lobular 1030 (15.9) 26,723 (16.7) 850 (15.3) 919 (16.5)
 Favorable 676 (10.4) 8284 (5.2) 504 (9.1) 501 (9.0)
 Others 152 (2.3) 2196 (1.4) 58 (1.0) 62 (1.1)
Grade    < 0.001    0.911
 I 2180 (33.7) 48,713 (30.4)   1934 (34.8) 1965 (35.3)  
 II 2505 (38.7) 68,905 (43.0) 2270 (40.8) 2263 (40.7)
 III 1048 (16.2) 35,381 (22.1) 863 (15.5) 853 (15.4)
 Unknown 741 (11.4) 7142 (4.5) 494 (8.9) 480 (8.6)
ER    < 0.001    0.776
 Negative 678 (10.5) 20,623 (12.9)   518 (9.3) 540 (9.7)  
 Positive 5006 (77.3) 132,246 (82.6) 4511 (81.1) 4492 (80.8)
 Unknown 790 (12.2) 7272 (4.5) 532 (9.6) 529 (9.5)
PR    < 0.001    0.861
 Negative 1357 (21.0) 36,191 (22.6)   1087 (19.5) 1107 (19.9)  
 Positive 4211 (65.0) 114,492 (71.5) 3881 (69.8) 3855 (69.3)
 Unknown 906 (14.0) 9458 (5.9) 593 (10.7) 599 (10.8)
Chemotherapy    < 0.001    0.246
 No 5947 (91.9) 112,270 (70.1)   5109 (91.9) 5075 (91.3)  
 Yes 527 (8.1) 47,871 (29.9) 452 (8.1) 486 (8.7)
  1. NHW non-Hispanic white, NHB non-Hispanic black, NHAIAN non-Hispanic American Indian/Alaska native, NHAPI non-Hispanic Asian or Pacific Islander, NA not available, ER estrogen receptor, PR progesterone receptor